CTOs on the Move

New Hanover Regional Medical Center

www.nhrmc.org

 
New Hanover Regional Medical Center is a not-for-profit health care system serving southeastern North Carolina and northeastern South Carolina. A teaching hospital, regional referral center, and Level 2 Trauma Center, NHRMC is dedicated to providing a wide range of health care services. Our mission is Leading Our Community to Outstanding Health, a bold statement that reinforces our goal to reach far beyond the walls of our hospitals and into the communities that rely on us for their care.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.nhrmc.org
  • 2131 S. 17th Street
    Wilmington, NC USA 28401
  • Phone: 910.815.5188

Executives

Name Title Contact Details
Eddie Parrish
Chief Information Security Officer Profile
Joe Norris
Interim Chief Information Officer Profile

Similar Companies

Pain Management Service

Pain Management Service is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Endependence Center

Endependence Center is a Norfolk, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arizona Medical Spine Inst

Arizona Medical Spine Inst is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merritt Based Medicine

Merritt Based Medicine is a medical student media platform that provides resources for applying to medical school, tips for CV and application building for fellow medial students, advocates that mental health matters, pre med motivation, and so much more!

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.